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Background: Hypoxia-induced endothelial cell dysfunction has been implicated in
increased cardiovascular disease associated with obstructive sleep apnea syndrome
(OSAS). OSAS mediates hypertension by stimulating angiotensin II (Ang II) production.
Hypoxia and Ang II are the major stimuli of vascular endothelial growth factor
(VEGF), which is a potent angiogenic cytokine and also contributes to the
atherogenic process itself.
Methods & results: We observed serum Ang II and VEGF levels and peripheral blood
mononuclear cell (PBMC) and neutrophil VEGF expression. Compared to controls,
subjects with OSAS had significantly increased levels of serum Ang II and VEGF and
VEGF mRNA expression in their leukocytes. To examine whether Ang II stimulates
VEGF expression in OSAS, we treated PBMCs obtained from control subjects with Ang
II and with an Ang II receptor type 1 (AT1) blocker, olmesartan. We observed an
increased expression of VEGF in the Ang II-stimulated PBMCs and decreased in VEGF
mRNA and protein expression in the PBMCs treated with olmesartan.
Conclusions: These findings suggest that the Ang II-AT1 receptors pathway
potentially are involved in OSAS and VEGF-induced vascularity and that endothelial
dysfunction might be linked to this change in Ang II activity within leukocytes of
OSAS patients.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Obstructive sleep apnea syndrome (OSAS) is asso-
ciated with considerable cardiovascular morbidityed.
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OSAS as an independent risk factor for both
nocturnal and diurnal hypertension.3–5 Further-
more, the few published studies on 24 h blood
pressure (BP) profiles in patients with OSA report
disturbances of the circadian BP rhythm.6,7 Møller
et al. have shown that OSAS mediates hypertension
by stimulating angiotensin II (Ang II) production.8
Ang II is a multifunctional bioactive peptide.
One important role of this peptide is regulation of
blood pressure and blood flow by modification of
vascular tone. Recently, many reports have
suggested the significance of Ang II as a growth
factor. Ang II has been shown to regulate growth
of vascular smooth muscle cells,9 induce local
expression of endothelin-1 (ET-1) and vascular
endothelial growth factor (VEGF).10,11 These
reports suggest that Ang II may play a role in the
development of a particular role in vascular
remodeling. VEGF is a dimorphic glycoprotein
with a molecular weight of 34,000–42,000, consist-
ing of two disulfide-linked peptide chains
having identical N termini.12 Four forms of VEGF
have been described: VEGF121 and VEGF165, which
are soluble products, and VEGF189 and VEGF206,
which remain primarily cell associated and lack the
mitogenic activity of the smaller forms.13,14 This
suggests that VEGF165 and VEGF121 are the pivotal
forms of VEGF. VEGF has been identified as a
cytokine that regulates differentiation, prolifera-
tion, migration, and survival of cells in the
microvascular endothelium.14,15 Along with a role
in angiogenesis, recent studies have shown that
VEGF may also contribute to the atherogenic
process itself. VEGF-induced monocyte activation
and migration16 have been shown to modulate the
growth of smooth muscle cells,17 and be closely
related to the progression of coronary athero-
sclerosis in humans18,19 and the extent of carotid
stenosis.20 Several reports have shown that OSAS
patients had elevated concentrations of VEGF that
correlated with the severity of the OSAS as
measured by the nocturnal hypoxia and apnea-
hypopnea index (AHI).21–23 It has also been
reported that amelioration of the nocturnal hypox-
ia by nasal continuous positive air pressure (nCPAP)
was associated with a significant decrease in
morning VEGF concentrations.24 In fact, hypoxia is
the major stimulus that upregulates VEGF synthesis
by controlling gene transcription and mRNA stabi-
lization.25,26 The involvement of Ang II in the
pathogenesis of vascular dysfunction in sleep
apnea, however, has not been investigated in
detail. We cannot exclude the possibility that
enhancement of VEGF expression is induced by
hypoxia-induced Ang II stimulation.Ang II may contribute to angiogenesis and
vascular dysfunction by VEGF biosynthesis in
patients with OSAS. In this study, we report that
Ang II is a potent stimulator of VEGF in leukocytes
through the Ang II receptor and that this Ang II-
induced VEGF upregulation is suppressed by an Ang
II receptor type 1 blocker, olmesartan.Materials and methods
Patients and control subjects
The study was approved by the ethics committee of
Iwate Medical University Hospital. The population
included nine control subjects and 8 OSAS patients
who participated in this study. All subjects were
recruited from Iwate Medical University Hospital
and provided written informed consent according
to the ethical protocols of our institution. To be
included in the study, patients had to be between
30 and 70 years of age, have a sleep laboratory
finding of an AHI more than 5, and have no illness in
the week preceding the study. Control subjects
without apnea were recruited from patients who
were referred for plysomnographic monitoring
because of suspected sleep apnea but were found
either to have primary snoring or an AHI score of
less than 5, provided that most of the disordered
breathing events were hypopneas not associated
with arterial oxygen desaturations. All subjects
were nonsmokers, asymptomatic and nonatopic
with normal spirometry.
Measurement of Ang II and VEGF
Blood samples were drawn from subjects’ ante-
cubital veins at the end of each sleep study (i.e.,
6 AM) and immediately centrifuged for 10min at
3000 rpm. The supernatant was frozen at 20 1C for
later analysis. Plasma Ang II was determined by
radioimmunoassay, as previously described.8
VEGF165 serum and cultured supernatant levels
were determined by a commercially available ELISA
test (R&D System Inc., Minneapolis, MN). This assay
is calibrated against a highly purified recombinant
human VEGF165, the major and most potent isoform
of VEGF.
Leukocyte isolation
Peripheral blood mononuclear cell (PBMC): Hepar-
inized venous blood was centrifuged on Histopaque
1077 (Sigma, Tokyo, Japan) at 1500G for 15min at
room temperature. Cells were collected at the
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phate-buffered saline (Invitrogen Corp., Carlsbad,
CA).
Neutrophils: Granulocyte/red blood cells (RBC)
pellets were collected. The RBCs were removed by
hypotonic lysis. Total neutrophil counts were
calculated using a hemacytometer.Cell culture
PBMC viability was determined by trypan blue
exclusion. Cells were plated at a density of
2 106 cells/1 cm2 growth area. Cells were resus-
pended in RPMI 1640 (Invitrogen Corp.) supplemen-
ted with 2mM L-glutamine, 10mM HEPES (N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid)
pH 7.2, and incubated overnight at 37 1C, 5% CO2
in air. PBMCs were stimulated with 100 nM Ang II. In
experiments to examine the effects of inhibitors,
the cultured cells were preincubated with olme-
sartan (RNH-6270, donated by Sankyo Pharmaceu-
tical Co, Tokyo, Japan), a specific AT1 receptor
blocker, for 2 h before 100 nM Ang II treatment and
then treated with Ang II concomitant with olme-
sartan (OL) for 24 h. Patient source (control vs
OSAS) did not affect responsiveness to Ang II and
OL.Table 1 Demographic, sleep, and clinical data of
control subjects and OSAS patients.
Control
(n ¼ 8)
OSAS
(n ¼ 8)
Age (y) 55.875.4 49.073.9
Sex (male/female ratio) 8:0 8:0
BMI (kg/m2) 28.071.6 30.571.2
AHI 2.370.6 54.678.8**
ARI (n/h TST) 13.370.3 65.479.1**
Average nightly SaO2 (%) 95.070.3 85.772.3**
Minimal SaO2 (%) 89.170.9 59.879.4**
Hypertension (n) 3 3
Ischemic heart disease (n) 0 0
Diabetes mellitus (n) 0 0
Values are expressed as mean7SEM. BMI ¼ body mass
index; AHI ¼ apnea-hypopnea index; ARI ¼ arousal index;
TST ¼ total sleep time. **P o 0:01:RNA isolation and RT-PCR
RNA was extracted from isolated PBMCs, neutro-
phils, and cultured PBMCs by RNeasy (Qiagen,
Valencia, CA) according to the procedure provided
by the vendor. RT-PCR was performed as described
previously.27 To amplify the known splice variants,
the following primer pairs that correspond to the 30
and 50 segments of the untranslated regions were
used: VEGF forward primer, 50-TCGGGCCTCCGAAA
CCA TGA-30; reverse, 50-CCTGGTGAGAGATCTGGT
TC-30; Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) forward primer, 50-TCGTGGAAGGACT-
CATG-30; reverse, 50-AGTGTAGCCCAGGATGCC-30.
The amplified PCR product sizes of the VEGF121,
VEGF165, VEGF189, VEGF206, and GAPDH RT-PCRs
were 516bp, 648bp, 720bp, 771bp and 231bp,
respectively. PCR without RT samples was per-
formed as a negative control. The PCR products
were separated by agarose gel electrophoresis and
stained with ethidium bromide. Signals were
quantified by densitometric scanning and normal-
ized against GAPDH. Control group or 0 h cultured
cells are standardized to 1.0.Statistical analysis
All data are expressed as the mean7SEM. The Tukey
multiple comparison procedure was used to assess
the statistical significance among the four groups.
The student unpaired t-test was also used to
examine changes between the control group and
the OSAS patients after testing data for normality
of the population using Kolmogorov–Smirnov test.Results
Patient characteristics
Eight OSAS patients and eight control subjects
completed the study. One patient from control
group discontinued because of an upper respiratory
tract infection. The clinical and demographic data
of the two groups are summarized in Table 1. These
data of the two groups demonstrated that patients
with OSAS had a moderate to severe OSAS with a
mean AHI of 54.678.8 events/h. The two groups
had no significant differences in age (P ¼ 0:64), BMI
(P ¼ 0:86), the rate of hypertension, ischemic
heart disease, and diabetes mellitus. There were
significant differences in arousal index (ARI),
average nightly SaO2, and minimal SaO2 (Po0:01).
Lung function parameters were within the normal
range in all persons studied. Six hypertensive
patients were well controlled at the outpatient
clinic. They had a well-documented history of
chronically elevated blood pressure (X140/90mm
Hg) without any apparent underlying cause. All
hypertensive patients took long-acting calcium
channel blockers, and were not taking any other
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Table 2 Specific laboratory data for Ang II and
VEGF.
Control
(n ¼ 8)
OSAS
(n ¼ 8)
Plasma Ang II (pg/ml) 37.972.3 51.975.2*
(coefficient of variation) (17.4) (28.26)
Plasma VEGF (pg/ml) 300.8735.3 502.1763.7*
(coefficient of variation) (33.24) (35.86)
*Po0:05:
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Figure 1 RT-PCR of VEGF mRNA on human leukocytes.
Control (C) and obstructive sleep apnea syndrome
(OSAS). VEGF mRNA expression was increased in periph-
eral blood mononuclear cell (PBMC) obtained from OSAS
patients. A: Representative RT-PCR. Signals were quanti-
fied by densitometric scanning and normalized against
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Control groups are standardized to 1.0. The values in B
are the mean7SEM of VEGF. *Indicates a statistically
significant (Po0:01) difference from control group as
determined by Student’s t-test.
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Figure 2 RT-PCR of VEGF mRNA on human leukocytes.
Control (C) and obstructive sleep apnea syndrome
(OSAS). VEGF mRNA expression was increased in neutro-
phils obtained from OSAS patients. A: Representative RT-
PCR. Signals were quantified by densitometric scanning
and normalized against Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH). Control group are standardized to
1.0. The values in B are the mean7SEM of VEGF. *Indicates
a statistically significant (Po0:01) difference from con-
trol group as determined by Student’s t-test.
S. Takahashi et al.1128medication. Antihypertensive drugs were discon-
tinued at least 5 days before the study.
Ang II and VEGF levels
The mean Ang II and VEGF plasma levels were
markedly elevated in the OSAS group when com-
pared to control group (Table 2).
VEGF mRNA expression in PBMC and
neutrophils
As shown in Figs. 1A,B and 2A,B, PCR analysis of
PBMCs as well as neutrophils detected VEGF mRNA
in patients with OSAS and showed a slight expres-
sion in neutrophils.
ARB reduce Ang II-induced VEGF expression
To investigate the effect of Ang II on VEGF
expression, PBMCs were stimulated with or without
100 nM Ang II. Ang II increased mRNA levels of VEGF
by 2.270.1-fold in PBMCs. To determine whether
an angiotensin II receptor blocker (ARB) effectively
inhibited VEGF mRNA expression, the cultured
PBMCs were preincubated with olmesartan for 2 h
before 100 nM Ang II treatment and then treated
with Ang II concomitant with olmesartan for 24 h.
As shown in Fig. 3A and B, Ang II-induced VEGF
mRNA expression was substantially reduced by
olmesartan. Similar results in protein level were
observed when supernatant of cultured PBMCs was
subjected to ELISA (Fig. 4). The abundance of the
VEGF protein decreased by 42% when pretreated
with olmesartan.Discussion
We have demonstrated that expression of both Ang
II and VEGF is significantly increased in the plasma
level of OSAS patients as compared to controlsubjects. In addition, we have shown that mono-
nuclear cells and neutrophils expressed the VEGF in
OSAS patients. Finally, we have shown that ARB
olmesartan inhibited Ang II-induced enhancement
of VEGF in vitro.
Prominent mechanisms in cardiovascular disease
such as endothelial dysfunction (the earliest man-
ifestation of atherosclerosis) were shown to be
accentuated in patients with sleep apnea.28,29 Two
major effects of OSAS are currently under intense
investigation: augmented sympathetic activation
associated with sleep fragmentation and increased
oxidative stress due to hypoxia/reoxygenation
injury and possibly hypercapnia. Both may nega-
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Figure 3 Effects of olmesartan on VEGF mRNA expres-
sion. Before the addition of 100 nM angiotensin II (Ang II),
peripheral blood mononuclear cells (PBMCs) obtained
from control subjects were pretreated with 100 nM
olmesartan (OL). Total RNA was isolated from cultured
PBMCs, and subjected to RT-PCR analysis. A: representa-
tive RT-PCRs. Signals were quantified by densitometric
scanning and normalized against Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). 0 h cultured cells are
standardize to 1.0. The values in B are the mean7SEM of
VEGF. *Indicates a statistically significant (Po0:01)
difference from the other three groups as determined
by the Tukey multiple comparison procedure.
*
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Figure 4 Levels of VEGF in peripheral blood mononuclear
cells (PBMCs) culture supernatants. Before the addition
of 100 nM Ang II, PBMCs were pretreated with the specific
AT1 receptor antagonist olmesartan 100 nM. Olmesartan
(OL) diminishes Ang II-induced VEGF secretion from
PBMCs. Results are expressed as mean7SEM. *Indicates a
statistically significant (Po0:01) difference from the
other three groups as determined by the Tukey multiple
comparison procedure.
Roles of Ang II in VGEF expression 1129tively affect cardiovascular function. In the present
study we focused on the expression of VEGF among
a variety of angiogenic factors because VEGF is
induced by hypoxia. VEGF is expressed by a variety
of cell types including aortic smooth muscle cells,30
macrophages,31 and myocytes.32 In addition, lym-
phocytes,33 neutrophils,34,35 and platelets36 have
been shown to express VEGF. It was reported that
PBMC- and neutrophil-derived VEGF contributed to
vascular injury and remodeling in Kawasaki dis-
ease.37 Furthermore, Mor et al. have recently
demonstrated that T-cells play a role in angiogen-
esis by delivering VEGF to inflammatory sites, and
that VEGF can augment proinflammatory T celldifferentiation.38 Our hypothesis is that expression
of Ang II and VEGF is increased in the plasma level
of individuals with OSAS patients. Using EIA, ELISA,
and RT-PCR, we showed that Ang II and VEGF
derived from leukocytes, especially PBMCs, were
significantly increased in the OSAS patients com-
pared with control subjects. It could be argued that
the increased Ang II concentration in OSAS patients
resulted from hypertension rather than from
breathing disorders per se. However, this possibility
seems as there were no significant differences in
the rate of hypertension between the two groups.
This will be further supported if significant reduc-
tion in plasma Ang II is demonstrated after
successful nCPAP treatment. Given our in vivo
data, we employed in vitro cultures of PBMCs
obtained from control, subjects to evaluate the
direct effect of Ang II on expression of VEGF. Our
study has shown that the increase in VEGF expres-
sion was detected after stimulation of Ang II in
PBMCs. As mentioned above, Ang II promotes
several critical processes in atherosclerosis such
as cell growth migration, release of growth factors,
adhesion and chemoattractant molecules, and
cytokines.39 Ang II may induce in vascular cells
the expression of the inflammatory cyclooxygenase
(COX)-2 gene40 and influence the extracellular
matrix turnover by regulating the activity of
prostaglandin E2-dependent metalloproteinase,41
enzymes that degrade extracellular matrix and
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lesion, and promote its rupture.42 Recently, Tazaki
et al. demonstrated that serum MMP-9 is increased
in OSAS patients when compared to normal
subjects.43 They speculated that elevated serum
MMP-9 might induce vascular events in OSAS
patients. Notably, all these effects appear
mediated by Ang II type 1 (AT1) receptors, as
reflected by in vitro studies using selective Ang II
receptor antagonists.41 The biological effects of
Ang II are mediated by Ang II receptors, of which
two major mammalian subtypes, AT1 and AT2, have
been identified.44 The AT1 receptor has been shown
to promote angiogenesis and microvascular angio-
genesis, which may be due to an AT1 receptor-
mediated upregulation of VEGF expression.45 We
pretreated cultured PBMCs with the selective AT1
receptor blocker olmesartan to confirm the role of
Ang II in regulating VEGF. VEGF expression de-
creased by 42%, suggesting that AT1 is essential to
VEGF expression after Ang II stimulation of PBMCs in
vitro. However, local activation of VEGF-producing
cells cannot explain the in vivo data in its entirety.
To our knowledge, there have not been any clinical
studies examining the effect of ARBs on VEGF
expression in OSAS patients. Our in vitro data may
be cautiously interpreted to support the concept of
AT1 receptor block for treatment of OSAS patients
with ongoing vascular remodeling.
Apart from Ang II stimulation, the expression of
the VEGF gene is stimulated by hypoxia through
mediation of hypoxia-inducible factor (HIF).46 HIF is
also responsible for the induction of a variety of
further hypoxia-sensitive genes. HIF-mediated gene
expression might occur in OSAS patients as a result
of repetitious nighttime hypoxia. In fact, our
preliminary data demonstrated that HIF mRNA
expression is increased in OSAS patients as com-
pared to the control group. Moreover, PBMCs that
were transfected with HIF antisense phosphorothio-
ate oligonucleotides, reduced expression of VEGF
mRNA (personal observation). However, we did not
detect correlations between serum VEGF and AHI in
our present study. It is possible that this study,
which was limited due to the focus on patients with
moderate to severe OSAS, was insufficient to
observe such a correlation.
In conclusion, our study addresses the possibility
that VEGF expression is induced, at least in part, by
increased Ang II and that the potential therapeutic
utility of ARBs as a novel approach for the
treatment of patients with OSAS. Since vascular
dysfunction is believed to be associated with
enhanced risk for occlusive vascular disease in
OSAS patients, the need for strategies aimed at
modulating the Ang II function is compelling.Acknowledgments
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